{"organizations": [], "uuid": "d0455b08166ae0a70cd6760b18342d9d7a8e21d3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180509.html", "section_title": "Archive News &amp; Video for Wednesday, 09 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-lipocine-receives-complete-respons/brief-lipocine-receives-complete-response-letter-for-tlando-from-u-s-fda-idUSASC0A0W2", "country": "US", "domain_rank": 408, "title": "BRIEF-Lipocine Receives Complete Response Letter For Tlando From U.S. FDA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.568, "site_type": "news", "published": "2018-05-09T19:01:00.000+03:00", "replies_count": 0, "uuid": "d0455b08166ae0a70cd6760b18342d9d7a8e21d3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-lipocine-receives-complete-respons/brief-lipocine-receives-complete-response-letter-for-tlando-from-u-s-fda-idUSASC0A0W2", "ord_in_thread": 0, "title": "BRIEF-Lipocine Receives Complete Response Letter For Tlando From U.S. FDA", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "lipocine inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}, {"name": "crl", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 9 (Reuters) - Lipocine Inc:\n* LIPOCINE RECEIVES COMPLETE RESPONSE LETTER FOR TLANDO FROM U.S. FOOD AND DRUG ADMINISTRATION\n* LIPOCINE - NEXT STEP TO REQUEST MEETING WITH FDA TO FURTHER EVALUATE DEFICIENCIES RAISED, TO AGREE ON PATH FORWARD FOR POTENTIAL APPROVAL OF TLANDO\n* LIPOCINE INC - CRL ALSO IDENTIFIED ADDITIONAL COMMENTS THAT ARE NOT CONSIDERED APPROVABILITY ISSUES\n* LIPOCINE INC - CRL IDENTIFIED FOUR DEFICIENCIES REGARDING ITS NEW DRUG APPLICATION FOR TLANDO Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-09T19:01:00.000+03:00", "crawled": "2018-05-10T17:34:46.000+03:00", "highlightTitle": ""}